Scopus is developing a better fungicide delivery system to replace standard liposome-package delivery with a “targeted” liposome that binds with pathogenic fungi. Scopus’ approach increases the anti-fungal effect of the drug while lowering the toxicity of host cells.
Tests on three of the most life-threatening fungal pathogens (Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans) have demonstrated the improved efficacy of Scopus’s anti-fungal drug.
Fungal diseases are responsible for 1,350,000 deaths globally each year and up to $100 billion in annual crop losses. In the U.S., the direct cost of medical treatment for fungal infections is estimated at $7.2 billion annually.
With a growing population vulnerable to fungal disease, Scopus sees a large potential market where patient outcomes could be improved and lives could be saved. The U.S. market for anti-fungal drugs is close to $5 billion annually, and the global market for agricultural fungicide is $16 billion.
Company website: Scopus
Back to companies
Location: United States, New York
Investors 1
| Date | Name | Website |
| - | Georgia Re... | gra.org |
Mentions in press and media 4
| Date | Title | Description | Source |
| 29.09.2021 | Scopus BioPharma : Subsidiary — Duet Therapeutics — Announce... | Scopus BioPharma's Subsidiary - Duet Therapeutics - Announces Release of Preclinical Data Being Pres... | marketscre... |
| 26.04.2021 | Scopus BioPharma Announces IND Submission to FDA for Lead Dr... | NEW YORK, April 26, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today an... | prnewswire... |
| 29.01.2021 | Scopus BioPharma Announces Closing of $9 Million Follow-On P... | NEW YORK, Jan. 29, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today ann... | prnewswire... |
| 26.01.2021 | Scopus BioPharma Announces Pricing of $9 Million Follow-On P... | NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today ann... | prnewswire... |